Genzyme Corporation

Chris Willis

Hanlan Liu

Renu Bhardwaj

Jianmei Kochling

Craig S Siegel

Judith Peterschmitt

Jeffrey Skell

Gerard Palace

The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.

Inhibitors of glucosylceramide synthase

The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described. 

Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase

Growing community of inventors

Southborough, MA, United States of America

Chris Willis